Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Allison Berger"'
Autor:
Glen J. Weiss, John S. Kauh, Bruce J. Dezube, Jeffrey W. Clark, Roger B. Cohen, Devalingam Mahalingam, James M. Cleary, Hélène M. Faessel, Allison Berger, Michael D. Pickard, George Mulligan, Kristin E. Burke, R. Donald Harvey, Geoffrey I. Shapiro, John Sarantopoulos
Publikováno v:
Clinical Cancer Research. 22:847-857
Purpose: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodyna
Autor:
Thea Kalebic, Neeraj Gupta, Lillian L. Siu, John S. Kauh, David Smith, Feng Gao, Ai Min Hui, Jeffrey R. Infante, Gordana Vlahovic, Allison Berger, Jianchang Lin, John A. Thompson, Deborah Berg, Guohui Liu, Stephen Tirrell, Daniel C. Sullivan, Alessandra Di Bacco
Publikováno v:
Investigational New Drugs
SummaryPurpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV) ixazomib, i
Autor:
Bret Bannerman, Larry Dick, Mark Rolfe, Li Yu, Paul Hales, Jie Yu, Frank J. Bruzzese, Mark Manfredi, Edmund Lee, Michael Fitzgerald, Yueying Cao, Khristofer Garcia, Jane Liu, Joe Bolen, Erik Kupperman, Jonathan L. Blank, Paul E. Fleming, Yu Yang, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Research. 70:1970-1980
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Autor:
Kristin E. Burke, Doug Bowman, Arijit Chakravarty, Mark D. Fleming, Jeffrey Ecsedy, A. A. McDonald, Vaishali Shinde, Stephen Tirrell, Stephen J. Blakemore, Allison Berger
Publikováno v:
Veterinary pathology. 51(1)
Immunohistochemistry-based biomarkers are commonly used to understand target inhibition in key cancer pathways in preclinical models and clinical studies. Automated slide-scanning and advanced high-throughput image analysis software technologies have
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som